AbbVie Inc.
ABBVNYSEDrug Manufacturers - General • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for ABBV
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for ABBV
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports · filed 31 Jul 2026
Second-Quarter Earnings Exceed Expectations
Reported adjusted diluted EPS of $3.65 per share for the quarter ended June 30, 2026, exceeded the same-quarter consensus estimate of $3.61 per share.
Revenue Growth Accelerates Year Over Year
Net revenues for the second quarter of 2026 reached $16.99 billion, representing a 10.16% increase from $15.42 billion in the same quarter of 2025.
Guidance Adjusted for Acquisition
AbbVie updated its 2026 adjusted diluted EPS guidance range to $13.87 - $14.07, incorporating a $0.14 dilutive impact from the proposed Apogee Therapeutics acquisition.
Operating Margins Expand
The adjusted operating margin ratio for the second quarter was 48.3 percent, compared to a GAAP operating margin ratio of 37.9 percent.
Rinvoq Receives EU Approval
The European Commission approved Rinvoq for the treatment of non-segmental vitiligo, marking the first systemic medication approval in the EU for this condition.
Apogee Therapeutics Acquisition Announced
AbbVie announced a definitive agreement to acquire Apogee Therapeutics, including its pipeline of clinical-stage candidates for inflammatory and immunological diseases, with a close anticipated in the third quarter of 2026.
Price Chart
NYSE:ABBV via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
ABBVAbbVie Inc. | $255.48 | $451.5B | 25.2x | 18.2x | +10.4% | 23.5% | 4.0% |
Company Profile
About the Company
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Next Earnings Date
Oct 29, 2026
Loading latest news...